Export-Reliant Indian Drug Industry Faces Fall Of Rupee Value
This article was originally published in PharmAsia News
Executive Summary
India's pharmaceutical industry is discovering it might not be as immune to the global financial crisis as previously believed. Indian pharmas normally would have been expected to continue reaping the rewards of drug exports still needed worldwide, but the value of the rupee has fallen enough to counterbalance any of those gains. Part of the negative impact is due to the fact the capital used to pay for products that India exports has to be weighed against the reduced value of the rupee. The situation means at least a temporary freeze on expansion through acquisitions and cutbacks of expenses by Indian drug makers. (Click here for more
You may also be interested in...
Economic Downturn May Hit Indian Drug Exports; Research Contracts May Dry Up
MUMBAI - Adverse economic conditions across several countries is likely to hit exports of Indian pharmaceutical companies for the current and the next year
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.